Yüklüyor......
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors
Background This phase 1, single-center, nonrandomized, single-arm, open-label, dose-escalation study, evaluated the tolerability of crenigacestat, a γ-secretase inhibitor as an oral Notch inhibitor in Japanese patients with advanced solid tumors. Methods The study consisted of 2 dose levels of creni...
Kaydedildi:
| Yayımlandı: | Invest New Drugs |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer US
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7960611/ https://ncbi.nlm.nih.gov/pubmed/32939607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-01001-5 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|